Affiliation:
1. Department of Pharmacotherapy and Outcomes Science Virginia Commonwealth University School of Pharmacy Richmond Virginia USA
2. Department of Pharmacy Children's Hospital of Richmond at Virginia Commonwealth University Richmond Virginia USA
3. Department of Pharmacy Atrium Health Wake Forest Baptist Winston‐Salem North Carolina USA
4. Division of Pediatric Pulmonary and Sleep Medicine Children's Hospital of Richmond at Virginia Commonwealth University Richmond Virginia USA
Abstract
AbstractUse of proton‐pump inhibitors (PPIs) is common among people with cystic fibrosis (pwCF) both for the management of suspected GERD, as well as pancreatic enzyme replacement therapy augmentation. Despite their use, limited data exist to demonstrate a clinically significant impact of PPIs on key endpoints in pwCF. Furthermore, the advent of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy may modify the need for use. These notions, coupled with the potential for adverse outcomes associated with long‐term PPI use in pwCF, should facilitate re‐evaluation of long‐term PPI use in pwCF and promote potential deprescribing. Despite limited data on PPI deprescribing in pwCF, it intuitively mirrors the existing guidance in adults in the general population, but with added consideration given to tapering strategy, and monitoring for CF‐specific outcomes such as nutritional and respiratory status. The development of a monitoring and re‐initiation plan is key to reducing deprescribing inertia. This review aims to summarize the evidence that details the concern for long‐term use of PPIs and provide CF clinicians with rationale and guidance on how to approach deprescribing in their practice.
Reference88 articles.
1. Cystic fibrosis;Rowe SM;N Engl J Med,2005
2. Increasing life expectancy in cystic fibrosis: advances and challenges;McBennett KA;Pediatr Pulmonol,2022
3. Cystic fibrosis: nutritional consequences and management;Dodge JA;Best Pract Res Clin Gastroenterol,2006
4. Nutritional growth retardation is associated with defective lung growth in cystic fibrosis: a preventable determinant of progressive pulmonary dysfunction;Thomson MA;Nutrition,1995
5. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto;Corey M;J Clin Epidemiol,1988